losartan has been researched along with arginyl-glycyl-aspartic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashizawa, N; Do, YS; Giachelli, CM; Graf, K; Hsueh, WA; Meehan, WP; Nunohiro, T; Tuan, TL | 1 |
| Blankesteijn, WM; Daemen, MJ; Fujimoto, A; Fujimoto, S; Hofstra, L; Isobe, S; Li, P; Lovhaug, D; Narula, J; Narula, N; Petrov, A; Pitt, B; Reutelingsperger, C; Smits, JF; van den Borne, SW; Vannan, MA; Wong, ND; Zandbergen, HR; Zannad, F | 1 |
2 other study(ies) available for losartan and arginyl-glycyl-aspartic acid
| Article | Year |
|---|---|
Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction.
Topics: Angiotensin II; Animals; Antibodies, Blocking; Antibodies, Monoclonal; Biphenyl Compounds; Blotting, Northern; Cells, Cultured; Collagen; DNA; Fibroblasts; Hypertension, Renovascular; Hypertrophy, Left Ventricular; Imidazoles; Immunohistochemistry; Integrins; Losartan; Myocardium; Oligopeptides; Osteopontin; Proteins; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sialoglycoproteins; Tetrazoles; Wound Healing | 1996 |
Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Carbocyanines; Cardiovascular Agents; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Fibrillar Collagens; Fibroblasts; Fibrosis; Losartan; Mice; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Oligopeptides; Predictive Value of Tests; Spironolactone; Technetium; Tomography, Emission-Computed, Single-Photon; Ventricular Function, Left; Ventricular Remodeling | 2009 |